Detail akcie Alkermes online

Business Summary: Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Alkermes Plc revenues increased 50% to $1.66B. Net income before extraordinary items totaled $519.2M vs. loss of $33.2M. Revenues reflect Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA segment increase from $115.7M to $486.1M, LYBALVI segment increase of 100% to $191.9M, United States segment increase of 60% to $1.49B. Net Income reflects Interest Income increase from $7.6M to $30.9M (income).